Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Yiyin ZhangChao YangHe ChengZhiyao FanQiuyi HuangYu LuKun FanGuopei LuoKaizhou JinZhengshi WangChen LiuXian-Jun YuPublished in: Journal of hematology & oncology (2018)
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
Keyphrases
- poor prognosis
- radiation therapy
- long non coding rna
- end stage renal disease
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- minimally invasive
- cancer therapy
- small molecule
- prognostic factors
- case report
- type diabetes
- coronary artery disease
- peritoneal dialysis
- cell therapy
- acute coronary syndrome
- adipose tissue
- metabolic syndrome
- current status
- skeletal muscle
- bone marrow
- quality improvement
- replacement therapy
- rectal cancer
- smoking cessation